|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||526.00 - 545.00|
|52 Week Range||301.00 - 545.00|
|Beta (5Y Monthly)||0.71|
|PE Ratio (TTM)||62.24|
|Forward Dividend & Yield||2.75 (0.52%)|
|Ex-Dividend Date||Apr 30, 2020|
|1y Target Est||N/A|
- Cryoport as a preferred partner for Lonza in the transport and delivery of patient tissues on a global basis - Partnership incorporates Cryoport's Cryoportal® Logistics Management Platform, SmartPak ...
Mesoblast expects to complete filing of the rolling Biologics License Application (BLA) submission to the US Food and Drug Administration (FDA) by the end of this year. On acceptance of the filing, the product candidate is eligible for FDA priority review under its existing Fast Track designation, providing for an expedited review period. The agreement provides for Lonza to expand its Singapore cGMP facilities if required to meet long-term growth and capacity needs for the product.